Treatment of lupus skin involvement with quinacrine and hydroxychloroquine. - Wikidata - wikimedia - TriplyDB

Treatment of lupus skin involvement with quinacrine and hydroxychloroquine.

Treatment of lupus skin involvement with quinacrine and hydroxychloroquine.

http://www.wikidata.org/entity/Q41938203

about

Beyond DNA binding - a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancers Cutaneous lupus and the Cutaneous Lupus Erythematosus Disease Area and Severity Index instrument Long-term response to hydroxychloroquine in patients with discoid lupus erythematosus.Treatment of cutaneous lupus.Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis.Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis.Hydroxychloroquine and smoking in patients with cutaneous lupus erythematosus.New insights into mechanisms of therapeutic effects of antimalarial agents in SLE.Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.A Quinacrine Analogue Selective Against Gastric Cancer Cells: Insight from Biochemical and Biophysical Studies.Cutaneous Lupus Erythematosus: An Update on Pathogenesis, Diagnosis and Treatment.Prevention of Recurrent Thrombosis in Antiphospholipid Syndrome: Different from the General Population?Quinacrine Suppresses Tumor Necrosis Factor-α and IFN-α in Dermatomyositis and Cutaneous Lupus Erythematosus.

P2860

Q28743513-CF42D7F3-D657-43AD-832F-450D2B9162DC Q34561606-217B5A6E-D55A-4CE7-BB47-5D226BECC83F Q34650392-F26ED6C9-30A2-4C94-B565-83E5ECBF126D Q35633324-6826CD02-6A9F-4B85-AC91-8F863F5CB8EA Q35764302-6A60E4A8-7620-452C-A4A4-F15C7AEC2A25 Q36257051-92ADAACF-E284-4AB4-8434-73010BE42B45 Q38009852-39B6AF35-54DF-4707-9E67-0EE4230BE838 Q38026787-08458998-0E05-4BDF-8FC0-7FA8D68D8656 Q38205079-2CE8B6BE-239C-42D5-87AD-EE6E1556C5BB Q38730329-0114C1B6-DF0A-4AFD-8EEE-16FA1470D4E3 Q38731631-69736CC2-6D33-4ACD-897D-9E0337A05FDA Q38794847-0844D37E-BC93-43F7-B1A7-755F9A55198D Q47760514-F63B9C58-1C89-4614-BF10-512FE5BA57BE

P2860

Treatment of lupus skin involvement with quinacrine and hydroxychloroquine.

http://www.wikidata.org/entity/Q41938203

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Treatment of lupus skin involvement with quinacrine and hydroxychloroquine.

@en

type

label

Treatment of lupus skin involvement with quinacrine and hydroxychloroquine.

@en

prefLabel

Treatment of lupus skin involvement with quinacrine and hydroxychloroquine.

@en

P1433

Q41938203-39091190-C11A-4082-97C6-2101C3BA7AF7

P1476

Q41938203-FD1230AA-A6B0-4DC8-A557-A44C3E51E112

P2093

Q41938203-0268781B-C46D-4E27-B663-9A8F89AD7B87

Q41938203-65E11BB3-266A-4369-AB37-CD9C53FC5769

Q41938203-7ABF4ED5-3905-4C55-A5A4-047F36E473A6

Q41938203-A6B25B0D-3585-4725-A5FA-62D1805939F5

Q41938203-E2B6D77C-9277-4975-A7AC-F18E209C8C0A

P2860

Q41938203-1718B08C-B784-49F7-AEDD-0D522982B969

Q41938203-33A62D21-735A-43C9-8B53-2655414E9DAC

Q41938203-420E3ED6-3BD6-497D-B18C-69374FAEBFF9

Q41938203-71D0EB93-6FB7-4DFD-9030-160B4B1A7F0A

Q41938203-81B3694B-AD54-46A4-90D8-A721F57FCA7F

Q41938203-905F4CDA-294D-46A7-A262-C6B8751F0B5C

Q41938203-9FB02B70-0798-4A00-A686-0B9A6936B30C

Q41938203-B4C1249D-A1FD-4487-AED8-1733A4969B6B

Q41938203-C0C9602F-1A71-42E0-8E4E-C83E9942D462

Q41938203-DAB4CAC3-37D7-406A-A23A-25D996BFFCE0

P304

Q41938203-57103B52-2050-4B41-BB3F-E2B00AC26F05

P31

Q41938203-A8A86C74-4B5D-4411-B9A5-2ECDF562EF1B

P356

Q41938203-FF7F212A-EDFA-4CC1-9C58-461215E924AB

P433

Q41938203-0A4771E8-5B2B-4FD2-907D-510E4188DA4C

P478

Q41938203-86019284-6A1C-4A43-AD2D-359111A76093

P50

Q41938203-593B1648-D9E2-4D35-9B5A-B5F6AE1BD348

Q41938203-B162B8B1-3FE9-4573-9A0C-8244C2DBA6F7

Q41938203-B5564084-9EF4-4147-AF7A-276314AB7E49

Q41938203-BE8D6E80-2E34-4CCF-8C78-1B153C561A8D

P577

Q41938203-66E3C642-BAC1-4A05-A2AA-5EFBEE346D2A

P698

Q41938203-D53A7B1D-3DD7-4E14-B771-818350B37637

P921

Q41938203-FA525B51-F917-4B16-8979-B1BAD91B5B9F

P356

0961203308101714

P1433

P1476

Treatment of lupus skin involvement with quinacrine and hydroxychloroquine

@en

P2093

C Bazzani

http://www.w3.org/2001/XMLSchema#string

C Zane

http://www.w3.org/2001/XMLSchema#string

I Cavazzana

http://www.w3.org/2001/XMLSchema#string

R Cattaneo

http://www.w3.org/2001/XMLSchema#string

R Sala

http://www.w3.org/2001/XMLSchema#string

P2860

The 1982 revised criteria for the classification of systemic lupus erythematosus

Mepacrine induced hepatitis

Antimalarial therapy: a panacea for mild lupus?

Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group

Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit.

Subacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological, and genetic findings.

The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus.

The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination.

Identification of antibodies to acidic antigens by counterimmunoelectrophoresis

Quinacrine added to ongoing therapeutic regimens attenuates anticardiolipin antibody production in SLE.

P304

735-739

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0961203308101714

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

Angela Ceribelli

Piergiacomo Calzavara-Pinton

P577

2009-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19502270

http://www.w3.org/2001/XMLSchema#string

P921

hydroxychloroquine